Results 1 to 10 of about 9,454,527 (233)

New Hypoglycemic Drugs: Combination Drugs and Targets Discovery [PDF]

Frontiers in Pharmacology, 2022
New hypoglycemic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i), which brings more options for the treatment of type 2 diabetes ...
Xiayun Ni, Lei Zhang, Xiaojun Feng, Liqin Tang   +3 more
doaj   +3 more sources

Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan [PDF]

BMC Ophthalmology, 2020
Background Poor persistence with glaucoma therapy can lead to disease progression and subsequent blindness. Persistence with second-line glaucoma combination treatment in a Japanese real-world setting and whether it differed from fixed and unfixed ...
Kenji Kashiwagi, Eriko Chono, Sarah Koesters, Poh Sin Yap   +3 more
doaj   +3 more sources

Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan [PDF]

Frontiers in Medical Technology
BackgroundAlthough a variety of drug delivery devices have been launched in recent years, few studies have comprehensively investigated the market trends of combination drugs and medical devices approved or certified in Japan and the regulatory ...
Makiko Mochizuki, Hideki Maeda
doaj   +2 more sources

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

Clinical Epigenetics, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +2 more sources

Study of possibility physical interactions antimalarial combination drugs [PDF]

Infectious Disease Reports, 2020
Identification of solid state to investigate the possibility of physical interaction between Antimalarial Artemisinin Combination Treatment base Artesunate (AS) and Amodiaquine (AQ) by hot contact method Kofler, cold contact method (crystallization ...
Timbul Partogi H. Simorangkir
doaj   +2 more sources

Epigenetic polypharmacology: from combination therapy to multitargeted drugs [PDF]

Clinical Epigenetics, 2016
The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chemical entities that exhibit high selectivity and potency for a particular target.
A Anighoro, A Dey, A Ganesan, A Mai, A Nudelman, AF Fliri, B Al-Lazikani, B Knoechel, B Meunier, BC Smith, BC Smith, BC Smith, BE Gryder, C Choudhary, C Corminboeuf, C Liu, C Qian, C Tang, C Yu, C Zwergel, C-W Chen, CM Fillmore, CM Grozinger, CY Fong, D Bixby, D Gallenkamp, D Matei, D Passarella, D Rotili, D Sharma, DA Mele, E Bicaku, E Borretto, E Nicodeme, F Sun, F-W Peng, G Zhang, G-L Chen, GE Winter, GL Verdine, H Patel, HS Bandukwala, HS Takhar, J Fischer, J Lu, J Schneider, J Zhao, J Zuber, J-B Chen, J-F Couture, J-PJ Issa, JC Culhane, JL Avalos, JM Burg, JS Kirk, K Agger, K Chen, K K-p, K Pruitt, K Zhao, KB Daniel, KT Thurn, L Chen, L Chen, LK Gediya, M Buchwald, M De los Santos, M Yang, M Zuo, MA Dawson, MA Dawson, MA Park, MB Poulin, MC Chen, MJ Keiser, MM Singh, MS Finnin, N Geva-Zatorsky, OW Rokhlin, P Anand, P Bamborough, P Filippakopoulos, P Hu, P Hu, P Jones, P Rathert, PA Marks, PK Mazur, PN Munster, Q Wang, R Anand, R Morphy, R Morphy, R Nimmanapalli, R Pereira, R Pili, R Álvarez, RA Copeland, RA Juergens, RL Momparler, S Daujat, S Klimasauskas, S Mahboobi, S Mahboobi, S Zhao, SC Hodawadekar, SJ Atkinson, SS Ng, T Beckers, T Finkel, T Kokkola, T Qiu, T Vaissiere, T-G Lee, TH Luu, TJ Galloway, TM Pitts, W Guerrant, WF Hawse, X Cai, X Cheng, X Sun, X Zhang, Y Ling, Y Zhang, Z Chen   +125 more
core   +2 more sources

Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture

Communications Biology, 2022
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of
Xuanting Wang, Carolina Q. Sacramento, Steffen Jockusch, O. Chaves, C. Tao, N. Fintelman-Rodrigues, Minchen Chien, J. Temerozo, Xiaoxu Li, Shiv Kumar, W. Xie, D. Patel, Cindy Meyer, Aitor Garzia, T. Tuschl, P. Bozza, J. Russo, T. M. Souza, J. Ju   +18 more
semanticscholar   +1 more source

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Biomedicines, 2021
As a public health emergency of international concern, the highly contagious coronavirus disease 2019 (COVID-19) pandemic has been identified as a severe threat to the lives of billions of individuals.
Liyan Yang, Zhonglei Wang
semanticscholar   +1 more source

Therapeutic evaluation of homeopathic treatment for canine oral papillomatosis [PDF]

, 2020
Aim: A study was conducted to evaluate the ameliorative potential of homeopathic drugs in combination (Sulfur 30C, Thuja 30C, Graphites 30C, and Psorinum 30C) in 16 dogs affected with oral papillomatosis which was not undergone any previous treatment ...
Kumar, M. Asok, Pavulraj, Selvaraj, Raj, P. Albert Arockia, Sabithabanu, S., Sangeetha, S., Shanmugapriya, R.   +5 more
core   +2 more sources

SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets

Genomics, Proteomics & Bioinformatics, 2022
Combinatorial therapies have been recently proposed to improve the efficacy of anticancer treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug combination datasets.
Shuyu Zheng, Wenyu Wang, Jehad Aldahdooh, A. Malyutina, Tolou Shadbahr, A. Pessia, Jing Tang   +6 more
semanticscholar   +1 more source